Belzutifan as a possible novel treatment for sporadic central nervous system hemangioblastoma: a report of two cases and focused review of the literature
- 1Department of Neurology, Medical College of Wisconsin
- 2Department of Neurosurgery, Medical College of Wisconsin
Abstract
Objective: To provide a review of hemangioblastoma treatment and to report a new treatment option for sporadic, non-von Hippel-Lindau (VHL) associated central nervous system hemangioblastomas (CNS-HBs).
Background: Belzutifan is FDA-approved for the treatment of VHL associated cancers including renal cell carcinoma, pancreatic neuroendocrine tumors and CNS-HBs as a hypoxia-inducible factor-2α inhibitor. The efficacy of belzutifan is unclear for sporadic, non-vHL associated CNS-HBs, a disease entity with limited systemic options.
Discussion: A 23-year-old female presented with a posterior fossa hemangioblastoma which was then resected. At initial recurrence, she completed fractionated radiation therapy with a positive radiographic response. She had multiple symptomatic radiographic recurrences that underwent additional resection. After her fourth recurrence, surgery as well as radiation were not felt to be a reasonable option. Belzutifan 120 mg daily was started. Two months later, she had radiographic improvement with reduction in size of the posterior fossa hemangioblastoma, which has been maintained after 24 months of treatment. A second case is a 33-year-old male with a C7-T1 non-vHL hemangioblastoma that was resected and radiated at recurrence. Nine years later, the patient had radiographic progression that was not amenable to surgery or radiation. Belzutifan was started, which resulted in radiographic and subjective symptomatic improvement.
Conclusion: We present two cases of sporadic recurrent hemangioblastoma with radiographic improvement to belzutifan, along with a review of hemangioblastoma treatment. To the best of our knowledge, these are the first two cases of radiographic improvement in sporadic, non-VHL associated CNS-HB from the use of belzutifan.
Related
- Does the Disease-free Survival Benefit of Adding Belzutifan to Adjuvant Pembrolizumab Persist Beyond the Planned Treatment Period? A Reconstructed Individual Patient Data Analysis of Phase 3 Renal Cell Carcinoma Trials
- Possible association of pyogenic liver abscess with an inflamed sigmoid colonic lipoma: a case report and literature review
- Efficacy of Medical Treatment Options for Reducing the Risk of Bleeding in Patients With Sporadic and Familial Cerebral Cavernous Malformations: A Systematic Review and Network Meta-Analysis.
- A systematic review on the possible role of microRNA-155 in cancer treatment
- Suprasellar hemangioblastoma during pregnancy: illustrative case.
BibTeX
@article{bureau2026belzutifan,
title = {{Belzutifan as a possible novel treatment for sporadic central nervous system hemangioblastoma: a report of two cases and focused review of the literature}},
author = {Britta L. Bureau and Ataollah Shahbandi and Saman Shabani and Jennifer M. Connelly},
journal = {Frontiers in Oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.1935078},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1935078/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Belzutifan as a possible novel treatment for sporadic central nervous system hemangioblastoma: a report of two cases and focused review of the literature
AU - Britta L. Bureau
AU - Ataollah Shahbandi
AU - Saman Shabani
AU - Jennifer M. Connelly
PY - 2026
DA - 2026/10/26
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1935078
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1935078/full
AB - Objective: To provide a review of hemangioblastoma treatment and to report a new treatment option for sporadic, non-von Hippel-Lindau (VHL) associated central nervous system hemangioblastomas (CNS-HBs). Background: Belzutifan is FDA-approved for the treatment of VHL associated cancers including renal cell carcinoma, pancreatic neuroendocrine tumors and CNS-HBs as a hypoxia-inducible factor-2α inhibitor. The efficacy of belzutifan is unclear for sporadic, non-vHL associated CNS-HBs, a disease entity with limited systemic options. Discussion: A 23-year-old female presented with a posterior fossa hemangioblastoma which was then resected. At initial recurrence, she completed fractionated radiation therapy with a positive radiographic response. She had multiple symptomatic radiographic recurrences that underwent additional resection. After her fourth recurrence, surgery as well as radiation were not felt to be a reasonable option. Belzutifan 120 mg daily was started. Two months later, she had radiographic improvement with reduction in size of the posterior fossa hemangioblastoma, which has been maintained after 24 months of treatment. A second case is a 33-year-old male with a C7-T1 non-vHL hemangioblastoma that was resected and radiated at recurrence. Nine years later, the patient had radiographic progression that was not amenable to surgery or radiation. Belzutifan was started, which resulted in radiographic and subjective symptomatic improvement. Conclusion: We present two cases of sporadic recurrent hemangioblastoma with radiographic improvement to belzutifan, along with a review of hemangioblastoma treatment. To the best of our knowledge, these are the first two cases of radiographic improvement in sporadic, non-VHL associated CNS-HB from the use of belzutifan.
SN - 2234-943X
ER -